OSE Immunotherapeutics
Biotechnology Research • 
Nantes, Pays de la Loire, France • 51-100 Employees
Company overview
| Headquarters | 22, avenue Bénoni Goullin, NANTES, PAYS DE LA LOIRE 44200, FR |
| Phone number | +3301432978 |
| Website | |
| NAICS | 541714 |
| SIC | 899 |
| Keywords | Biotechnologie, Immunothérapie, Nsclc, Mdsc, Développement Clinique, Checkpoint Inhibitor, Immuno-Oncologie, Maladies Autoimmunes, Néo-Épitopes, Rectocolite Hémorragique, Sirp-Alpha, Polyarthrite Rhumatoïde |
| Founded | 2012 |
| Employees | 51-100 |
| Socials |
Key Contacts at OSE Immunotherapeutics
Nicolas Poirier
Chief Executive Officer
Romain Gret
Director Of Business Development, Global Market And Competitive Intelligence
Sylvie Jouve
Director Of Clinical Operations
Markus Goebel
Director
Caroline Chevalier
Director Clinical Operations
Fanny De Sa
Clinical Packaging And Supply Chain Director
Aurore Morello
Head Of Research, Director Of R&D Program
Kenechukwu Stephen
Sales Director
Vanessa Gauttier
Target Discovery Director
Thierry Gautheret
Ip Director - Directeur Propriété Industrielle
OSE Immunotherapeutics Email Formats
OSE Immunotherapeutics uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@ose-immuno.com), used 73.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@ose-immuno.com | 73.6% |
{first initial}.{last name} | j.doe@ose-immuno.com | 26.4% |
About OSE Immunotherapeutics
OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis). • Anti-SIRPα mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and combo; Phase 2 in CRM diseases planned end 2024. • ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. 4 proprietary drug discovery platforms • Pro-resolutive mAb platform • Myeloid Checkpoint platform • BiCKI® Platform • mRNA Therapeutic platform f
OSE Immunotherapeutics revenue & valuation
| Annual revenue | $19,600,000 |
| Revenue per employee | $242,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $62,600,000 |
| Total funding | $10,720,200 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
OSE Immunotherapeutics has 49 employees across 10 departments.
Departments
Number of employees
Funding Data
Explore OSE Immunotherapeutics's funding history, including investment rounds, total capital raised, and key backers.
OSE Immunotherapeutics Tech Stack
Discover the technologies and tools that power OSE Immunotherapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
Analytics
SEO
Issue trackers
Tag managers
Reverse proxies
JavaScript frameworks
Saudi Arabia
United States
Spain
United Kingdom
Frequently asked questions
4.8
40,000 users
